Clinical trials: Immunotherapy
Metastatic Breast Cancer
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
One important approach to change the natural history of advanced breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of…
- Trial name
- NCT00367250
- Testing
- Cetuximab, Trastuzumab
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT03321643
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Muscle Rigidity, Spasm
Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Stiff-man Syndrome (SMS) is a chronic, progressive disorder of the nervous system. It is associated with painful muscle spasms and rigidity involving muscles of the limbs, trunk, and neck.
- Conditions
- Muscle Rigidity, Spasm, Stiff Man Syndrome
- Trial name
- NCT00001550
- Testing
- IVIg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Urothelial Bladder Carcinoma
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the…
- Trial name
- NCT06133517
- Testing
- Sacituzumab govitecan, Zimberelimab, Domvanalimab
- Where
- 6 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
Metastatic Renal Cell Carcinoma
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC.
- Trial name
- NCT05858749
- Where
- United States
- Volunteers
- 494 people
- Sponsor
- Pfizer
NSCLC Stage IV
Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy
The aim of this prospective study is to evaluate the effects of an outpatient pulmonary rehabilitation program on the quality of life, performance and tumor growth of metastatic lung cancer patients receiving ongoing…
- Trial name
- OPAL (NCT06436625)
- Testing
- outpatient pulmonary rehabilitation
- Where
- Austria
- Volunteers
- 70 people
- Sponsor
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Melanoma
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.
- Trial name
- NCT02427893
- Testing
- Cobimetinib, Vemurafenib
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma Stage IV, Unresectable Melanoma
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab…
- Trial name
- NCT05309421
- Testing
- EVX-01, Pembrolizumab 25 MG/ML
- Where
- 4 sites in Australia, Italy
- Volunteers
- 17 people
- Sponsor
- Evaxion Biotech A/S
Low Grade Non-Hodgkin's Lymphoma, Adult
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Aims of this study are to describe the variation of QoL (Quality of Life) during the clinical management of low-grade lymphoma in elderly subjects and to identify the most important factors at diagnosis and during treatment with…
- Trial name
- NCT05524298
- Where
- 21 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Allergy
Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis
To find a test to elaborate a parameter for specific immunotherapy in allergic patients
- Trial name
- NCT00461721
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Hepatitis C, Chronic
Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus
The primary objective is to determine the safety of sub-cutaneous (SC) injections of TG4040 in non-cirrhotic, treatment-naïve patients chronically infected with HCV (genotype 1).
- Trial name
- NCT00529321
- Testing
- MVA-HCV (Immunotherapy)
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- Transgene
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
This clinical trial will evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Cell Cancer, Squamous
- Trial name
- NCT03336606
- Testing
- MEDI0562
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Colorectal Cancer
PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)
Phase I/II clinical trial investigates the safety, tolerability, immunogenicity and preliminary efficacy of multiple doses of PolyPEPI1018 CRC vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients…
- Trial name
- OBERTO (NCT03391232)
- Testing
- PolyPEPI1018 CRC Vaccine
- Where
- 2 sites in United States, Italy
- Volunteers
- 11 people
- Sponsor
- Treos Bio Zrt
Birch Pollen-related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Study of rBet v1 Tablets
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
- Trial name
- NCT00901914
- Testing
- rBet v 1
- Where
- 8 sites in Denmark, Finland and 6 more
- Volunteers
- 483 people
- Sponsor
- Stallergenes Greer
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Skin Toxicity, Immunotoxicity
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities
Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications.
- Trial name
- ImmunoSkin (NCT04929834)
- Testing
- Hydrating emollient + body lotion for immunotherapy-related side effects
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Jessa Hospital
Cutaneous Melanoma
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
- Trial name
- NCT03843593
- Testing
- Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of sintilimab combined with anlotinib and taxane-based chemotherapy in patients with recurrent (not unable to locally curative treatment) or…
- Trial name
- NCT07581821
- Testing
- Sintilimab + Anlotinib + taxane-based chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Ming-Yuan Chen
Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK)…
- Trial name
- NCT03882840
- Testing
- ITNK cell therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pancreatic Cancer Non-resectable
Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer
Pancreatic cancer (PDA) is the most lethal form of cancer, and the fourth-leading cause of cancer-related death in the United States, with a survival rate of less than 7%.There are currently no treatments found to be effective…
- Trial name
- V3-P (NCT03165591)
- Testing
- V3-P
- Where
- 2 sites in Mongolia
- Volunteers
- 30 people
- Sponsor
- Immunitor LLC